Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) EPS (Weighted Average and Diluted) (2016 - 2020)

GT Biopharma (GTBP) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with $3.47 as the latest value for Q4 2020.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 899.18% to $3.47 in Q4 2020 year-over-year; TTM through Dec 2020 was $3.47, a 899.18% increase, with the full-year FY2025 number at -$6.68, up 3.75% from a year prior.
  • EPS (Weighted Average and Diluted) was $3.47 for Q4 2020 at GT Biopharma, up from -$0.02 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $50.1 million in Q2 2018 to a low of -$50.1 million in Q3 2018.
  • A 5-year average of -$22360.8 and a median of -$0.09 in 2019 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 845989.63% in 2017, then soared 848020015.4% in 2018.
  • GT Biopharma's EPS (Weighted Average and Diluted) stood at $119.35 in 2016, then crashed by 86.64% to $15.94 in 2017, then crashed by 314416549.18% to -$50.1 million in 2018, then soared by 100.0% to -$0.43 in 2019, then skyrocketed by 899.18% to $3.47 in 2020.
  • Per Business Quant, the three most recent readings for GTBP's EPS (Weighted Average and Diluted) are $3.47 (Q4 2020), -$0.02 (Q1 2020), and -$0.43 (Q4 2019).